Regulation of ErbB Receptor Tyrosine Kinase Activities in Breast Cancer by the Kek Proteins

2001 ◽  
Author(s):  
Norbert Perrimon
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Erbb Receptor ◽  
Erbb Receptor Tyrosine Kinase

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

2010 ◽  
Vol 28 (8) ◽  
pp. 1301-1307 ◽  
Author(s):  
Harold J. Burstein ◽  
Yan Sun ◽  
Luc Y. Dirix ◽  
Zefei Jiang ◽  
Robert Paridaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Erbb Receptor ◽  
Receptor Tyrosine Kinase Inhibitor ◽  
Trastuzumab Treatment ◽  
Erbb Receptor Tyrosine Kinase ◽  
Positive Breast Cancer

Purpose Neratinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor. The efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-positive breast cancer—those with and those without prior trastuzumab treatment—in an open-label, multicenter, phase II trial. Patients and Methods Patients in the two cohorts (prior trastuzumab, n = 66; no prior trastuzumab, n = 70) received oral neratinib 240 mg once daily. The primary end point was the 16-week progression-free survival (PFS) rate for the evaluable population (prior trastuzumab, n = 63; no prior trastuzumab, n = 64), as assessed by independent review. Results The 16-week PFS rates were 59% for patients with prior trastuzumab treatment and 78% for patients with no prior trastuzumab treatment. Median PFS was 22.3 and 39.6 weeks, respectively. Objective response rates were 24% among patients with prior trastuzumab treatment and 56% in the trastuzumab-naïve cohort. The most common adverse events were diarrhea, nausea, vomiting, and fatigue. Diarrhea was the most frequent grades 3 to 4 adverse event, occurring in 30% of patients with prior trastuzumab treatment and in 13% of patients with no prior trastuzumab treatment, which prompted dose reductions in 29% and 4% of patients, respectively, but treatment discontinuation in only one patient. No neratinib-related, grades 3 or 4 cardiotoxicity was reported. Conclusion Oral neratinib showed substantial clinical activity and was reasonably well tolerated among both heavily pretreated and trastuzumab-naïve patients who had advanced, ErbB2-positive breast cancer. Diarrhea was the most common adverse effect but was manageable with antidiarrheal agents and dose modification.

Apple procyanidins affect several members of the ErbB receptor tyrosine kinase family in vitro

2013 ◽  
Vol 4 (5) ◽  
pp. 689 ◽  
Author(s):  
Nicole Teller ◽  
Matthias Roth ◽  
Melanie Esselen ◽  
Diana Fridrich ◽  
Ute Boettler ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Erbb Receptor ◽  
Kinase Family ◽  
Erbb Receptor Tyrosine Kinase ◽  
Receptor Tyrosine Kinase Family

scholarly journals ErbB Receptor Tyrosine Kinase: A Molecular Switch Between Cardiac and Neuroectoderm Specification in Human Pluripotent Stem Cells

Stem Cells ◽  
2016 ◽  
Vol 34 (10) ◽  
pp. 2461-2470 ◽  
Author(s):  
Chrishan J. A. Ramachandra ◽  
Ashish Mehta ◽  
Chong Hui Lua ◽  
Anuja Chitre ◽  
K. P. Myu Mai Ja ◽  
...  
Keyword(s):  
Stem Cells ◽  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Pluripotent Stem Cells ◽  
Molecular Switch ◽  
Human Pluripotent Stem Cells ◽  
Erbb Receptor ◽  
Erbb Receptor Tyrosine Kinase ◽  
Kinase A
Sign in / Sign up

Export Citation Format

Share Document